BIO Letter to USTR Ambassador Tai on Global Vaccine Distribution
June 30, 2021
We would like to provide you some updates on the U.S. and global biotechnology industry’s efforts to scale-up global vaccine production to address the global imbalance in access to COVID vaccines, and to request a close working relationship with USTR now that the WTO has agreed to have text-based discussions on COVID and intellectual property (IP) rights.
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
We would like to provide you some updates on the U.S. and global biotechnology industry’s efforts to scale-up global vaccine production to address the global imbalance in access to COVID vaccines, and to request a close working relationship with USTR now that the WTO has agreed to have text-based discussions on COVID and intellectual property (IP) rights.